With the COVID-19 pandemic exposing the critical need for domestic vaccine production, Korea signaled Friday that it intends to be among the nations capable of addressing this necessity, advancing a homegrown messenger RNA (mRNA) vaccine candidate into Phase II clinical trials. The Korea Disease Control and Prevention Agency (KDCA) and the National Institute of Health said pharmaceutical giant GC Biopharma submitted its Phase II trial plan to regulatory authorities. The filing marks a critical bridge between preliminary safety checks and the rigorous, large-scale human testing required to validate efficacy. For a nation that navigated the COVID-19 era largely reliant on Western biopharmaceutical giants, KDCA said the milestone represents not just routine medical progress but a calculated leap toward national self-reliance. At the heart of Seoul’s ambitious push is the mRNA Vaccine Development Support Program for Pandemic Preparedness. The initiative is built around the government's bid to engineer a versatile, domestic mRNA platform capable of producing a targeted vaccine within 200 d